Literature DB >> 6084526

Dipyridamole induces interferon in man.

A S Galabov, M Mastikova.   

Abstract

Thirty-six out of 40 healthy volunteers responded with a markedly elevated blood interferon (IFN) content to a single oral administration of dipyridamole (a 100 mg dose): 958.0 +/- 23.5 IU/ml serum at the 24th-48th hour. A hyporeactivity state to the repeated inducer application was found within the time interval of 4th-6th day. It was established that 7/8 of the dipyridamole-induced IFN represented IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6084526

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

1.  Dipyridamole, as an interferon inducer, versus placebo in the prevention of recurrences of condylomata acuminata after diathermocoagulation.

Authors:  G Mancuso; M Reggiani; R M Berdondini; A Errani
Journal:  Genitourin Med       Date:  1995-02

2.  New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.

Authors:  Yogendra Kanthi; Jason S Knight; Yu Zuo; David J Pinsky
Journal:  JCI Insight       Date:  2020-07-23

3.  Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.

Authors:  Kholoud F Aliter; Rami A Al-Horani
Journal:  Curr Pharm Des       Date:  2021       Impact factor: 3.116

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.